Ertapenem clearance during modeled continuous renal replacement therapy

International Journal of Artificial Organs

Volumn 31, Issue 12, 2008, Pages 1027-1034

  Stevenson, J M ^a   Patel, J H ^a   Churchwell, M D ^b   Vilay, A M ^a   Depestel, D D ^a   Sorgel F ^c   Kinzig, M ^c   Jakob, V ^c   Mueller, Bruce A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c Institute for Biomedical Research   (Germany)

Author keywords

Ertapenem; Hemofiltration; Renal dialysis; Renal replacement therapy

Indexed keywords

DIALYSIS; METABOLISM;

DIALYSATES; ERTAPENEM; HEMOFILTRATION; IN-VITRO MODELS; POLYSULPHONE; RENAL DIALYSIS; RENAL REPLACEMENT THERAPIES; SATURATION COEFFICIENT; SIEVING COEFFICIENT; TRANSMEMBRANES;

UREA;

CARBAPENEM; ERTAPENEM; POLYSULFONE; UREA;

ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; DIALYSATE; DIALYSIS MEMBRANE; DRUG CLEARANCE; DRUG DETERMINATION; FILTER; FLOW RATE; IN VITRO STUDY; ULTRAFILTRATION;

EID: 60749117489     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803101206     Document Type: Article

References (26)

1. Pesacreta M, Overberger P, Palevsky PM; VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol 2007; 2: 623-30.
2. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26-30.
3. Kindgen-Milles D, Journois D, Fumagalli R, et al. Study protocol: the Dose Response Multicentre International Collaborative Initiative (DO-RE-MI). Crit Care 2005; 9: 396-406.
4. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28: 3581-7.
5. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med 2001; 27: 978-86.
6. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27: 808-14.
7. Iregui M, Ward S, Sherman G, Fraser V, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8.
8. Aronoff GR, Bennett WM, Berns JA, et al. Drug prescribing in renal failure. 5th ed. Philadelphia, PA: American College of Clinical Physicians, 2007; 52-82.
9. Invanz: ertapenem for injection [package insert]. February 2008. Whitehouse Station, NJ: Merck, 2008. http://www.merck.com/product/usa/ pi_circulars/i/invanz/invanz_pi.pdf. Accessed Dec 11, 2008.
10. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65: 2151-78.
11. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
12. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-52.
13. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
14. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-54.
15. Golper TA. Update on drug sieving coefficients after dosing adjustments during continuous renal replacement therapies. Contrib Nephrol 2001; 132: 349-53.
16. Popick AC, Crouthamel WG, Bekersky I. Plasma protein binding of ceftriaxone. Xenobiotica 1987; 17:1139-45.
17. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000; 20: 635-43.
18. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 1996; 36: 1114-9.
19. Clisshold SP, Tood PA, Campoli-Richards DM. Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987; 33: 183-241.
20. Fish DN, Teitelbaum I, Abraham E: Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005; 49: 2421-8.
21. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42: 2417-20.
22. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45: 929-34.
23. Churchwell MD, Pasko DA, Btaiche IF, Jain J, Mueller BA. Trace element removal during in vitro and in vivo continuous hemodialysis. Nephrol Dial Transplant 2007; 22: 2970-7.
24. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 486-92.
25. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26-30.
26. Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005; 39: 352-6.